Across the recent three months, 6 analysts have shared their insights on Enovis (NYSE:ENOV), expressing a variety of opinions spanning from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Enovis, presenting an average target of $70.17, a high estimate of $75.00, and a low estimate of $62.00. Surpassing the previous average price target of $66.75, the current average has increased by 5.12%.

Analyzing Analyst Ratings: A Detailed Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Enovis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

For valuable insights into Enovis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Enovis analyst ratings.

Unveiling the Story Behind Enovis

Key Indicators: Enovis's Financial Health

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Enovis's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 8.78%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Enovis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -0.69%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Enovis's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.08%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Enovis's ROA stands out, surpassing industry averages. With an impressive ROA of -0.07%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Enovis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.

How Are Analyst Ratings Determined?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.